Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Trial ID or NCT#

NCT03439254

Status

recruiting iconRECRUITING

Purpose

The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

Official Title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Aijaz Ahmed, MD
Aijaz Ahmed, MD
Hepatologist, Transplant hepatologist
Professor of Medicine (Gastroenterology and Hepatology)

Contact us to find out if this trial is right for you.

Contact

Angela Fuller
650-721-4326

SEND MESSAGE

View on ClinicalTrials.gov